<SEC-DOCUMENT>0001193125-26-168538-index.html : 20260422
<SEC-HEADER>0001193125-26-168538.hdr.sgml : 20260422
<ACCEPTANCE-DATETIME>20260422080425
ACCESSION NUMBER:		0001193125-26-168538
CONFORMED SUBMISSION TYPE:	ARS
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260422
DATE AS OF CHANGE:		20260422
EFFECTIVENESS DATE:		20260422

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Taysha Gene Therapies, Inc.
		CENTRAL INDEX KEY:			0001806310
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				843199512
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		ARS
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39536
		FILM NUMBER:		26881331

	BUSINESS ADDRESS:	
		STREET 1:		3000 PEGASUS PARK DRIVE
		STREET 2:		SUITE 1430
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75247
		BUSINESS PHONE:		(214) 612-0000

	MAIL ADDRESS:	
		STREET 1:		3000 PEGASUS PARK DRIVE
		STREET 2:		SUITE 1430
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75247
</SEC-HEADER>
<DOCUMENT>
<TYPE>ARS
<SEQUENCE>1
<FILENAME>d942601dars.pdf
<DESCRIPTION>ARS
<TEXT>
Document 1 - file: d942601dars.pdf

</DOCUMENT>
</SEC-DOCUMENT>